Browsing Tag
Revolution Medicines
8 posts
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Tango Therapeutics (TNGX) soars on striking pancreatic cancer data, then moves to cash in
Tango Therapeutics soared 50%+ on early pancreatic cancer data, a 92% response rate for vopimetostat plus daraxonrasib, then filed a $500M offering to cash in.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
Tango Therapeutics raises $225m in equity offering and PIPE to fuel precision oncology pipeline
Find out how Tango Therapeutics’ $225 M equity and PIPE financing could reshape its precision-oncology strategy and investor sentiment.
Wall Street winners: Pony AI, ADMA Biologics, Luckin Coffee among top gainers
Find out which stocks led Wall Street on April 29, 2025, and why economic turbulence could shape their next moves. See the full list of today's biggest gainers.
Revolution Medicines’ Zoldonrasib demonstrates early antitumor potential in kras g12d mutant lung cancer at AACR 2025
Find out how Revolution Medicines’ new data on zoldonrasib could reshape KRAS G12D mutant lung cancer treatment strategies.